Startseite Kongressberichte 2020 Virtual Edition of the 25th Annual Congress of the European Hematology Association Oral Sessions Immunology Stem cell transplantation: Stem cell transplantation:

Stem cell transplantation - Clinical: Graft Versus Host Disease

 
 
Robert Zeiser, Nikolas von Bubnoff, Dietger Niederwieser, et al.
 
The authors of the abstract conclude: 
RUX showed a consistent clinically meaningful treatment benefit for pts with SR-aGvHD across different subgroups of baseline characteristics, including aGvHD grade at randomization, organ involvement, criteria for SR and transplant characteristics. ORR at Day 28 was significantly higher with RUX vs BAT in alignment with the response rate from the overall REACH2 study population.
————————————————————————————————————————————————————————
 
 
Robert Zeiser, Gérard Socié, Mark A. Schroeder, et al.
 
The authors of the abstract conclude: 
ITA added to CS for the initial treatment of aGVHD did not significantly improve Day 28 ORR, 6-mo NRM, or OS vs PBO plus CS; however, post-hoc analysis showed significant association with Day 28 CR rates and further analyses are needed to understand if this translated into clinical benefit.
————————————————————————————————————————————————————————
 
 
Si-Ning Liu, Lan-Ping Xu, Xiao-Hui Zhang, et al.
 
The authors of the abstract conclude: 
Thus, basiliximab is an effective and safe treatment for SR-aGVHD, which can also improve the long-term survival.
————————————————————————————————————————————————————————
 
 
Marta Fonseca-Santos, Maria Garcia-Alvarez, Luis Antonio Corchete-Sanchez, et al.
 
The authors of the abstract conclude: 

Our results confirm the significant role of ST2 and REG3a in haplo-SCT outcome in the largest single centre cohort to date of a homogeneous series of haplo-SCT. We also demonstrate, for the first time, its prognostic impact on days +7 and +14.

The incorporation of biomarkers to classical risk variables in haplo-SCT is promising. However, due to the discrepancy between different studies and the lack of standardization of laboratory methods, confirmation in prospective and larger series is required before its incorporation into the clinical practice.

————————————————————————————————————————————————————————
 
 
Amin Turki, Francis Ayuk, Gernot Beutel, et al.
 
The authors of the abstract conclude: 
The ML based scoring system based on organ stage involvement differentiated relevant clinical cohorts, which were successfully validated on external datasets.